| Print
Shuttle Pharmaceuticals Holdings Inc (SHPH)
Common SharesThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.
Address
Forecast key dates
| Name | Key Date |
|---|---|
| Shuttle Pharmaceuticals Holdings Inc Annual General Meeting for 2027 | 2027-05-21T12:00:00 |
| Shuttle Pharmaceuticals Holdings Inc First Quarter Earnings Results for 2027 | 2027-05-14T00:00:00 |
| Shuttle Pharmaceuticals Holdings Inc Annual Report for 2026 | 2027-03-31T00:00:00 |
| Shuttle Pharmaceuticals Holdings Inc Third Quarter Earnings Results for 2026 | 2026-11-13T00:00:00 |
| Shuttle Pharmaceuticals Holdings Inc Second Quarter Earnings Results for 2026 | 2026-08-13T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Shuttle Pharmaceuticals Holdings Inc Annual General Meeting for 2026 | 2026-05-21T12:00:00 |
| Shuttle Pharmaceuticals Holdings Inc First Quarter Earnings Results for 2026 | 2026-05-15T00:00:00 |
| Shuttle Pharmaceuticals Holdings Inc Annual Report for 2025 | 2026-03-31T00:00:00 |
| Shuttle Pharmaceuticals Holdings Inc Third Quarter Earnings Results for 2025 | 2025-11-13T00:00:00 |
| Shuttle Pharmaceuticals Holdings Inc Second Quarter Earnings Results for 2025 | 2025-08-13T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2026 AJ Bell. All rights reserved.